Nursing of chemotherapy of combined CIK with bevacizumab on terminal malignant tumor

VernacularTitle:高效CIK和贝伐单抗联合化疗治疗晚期恶性肿瘤的护理
Author: Huan LIN ¹ ; Fan WANG ; Shao-Zhen MO ; Guo-Dai HONG
Author Information

1. 518029,深圳大学第一附属医院肿瘤二科
Keywords: Antibodies,monoclonal; Antineoplastic combined chemotherapy protocols; Neoplasms
From: Chinese Journal of Modern Nursing 2013;19(13):1534-1536
CountryChina
Language:Chinese
Abstract: Objective To investigate the efficient care for the terminal malignant tumor therapy with CIK and bevacizumab,so as to reduce the adverse reactions and improve clinical outcomes.Methods A retrospective analysis on care methods and effects was conducted in 40 patients with terminal malignant tumor received CIK and bevacizumab chemotherapy.Results No patients was terminate therapy for serious adverse reactions of CIK and bevacizumab,and 3 cases of fever,2 cases of mild allergy,9 cases of hypertension,2 cases of urinary protein,5 cases of oral bleeding,1 case with scant hemoptysis,they were successfully finish the treatment plan after timely treated.Conclusions Appropriately formulating nursing interventions according to the treatment characteristics of CIK and bevacizumab can effectively prevent and mitigate the adverse reactions,and improve the efficacy.